Amanda Psyrri, MD-PhD, achieved her MD from the University of Patras, Greece in 1993. From 1996-2002, Prof. Psyrri did her Residency in Internal Medicine, followed by a Medical Oncology/Hematology Fellowship at Yale University School of Medicine & Yale Cancer Center in the USA. She is Board-Certified in Internal Medicine and Medical Oncology in the USA and Greece. Prof. Psyrri completed a research Fellowship in Cancer Virology at Prof. Daniel DiMaio's laboratory at Yale University (2000-2002). In 2002 she joined the Faculty of Medicine, Medical Oncology Section at Yale as an Instructor and was promoted to Assistant Professor in 2003.

At Yale, Prof. Psyrri led a clinical and translational research program in head and neck malignancies focusing on HPV-induced carcinogenesis and biomarkers. Prof. Psyrri's laboratory provided evidence for the causal association between HPV and oropharyngeal carcinoma and contributed to establishing p16 as surrogate biomarker for biologically and clinically relevant HPV infection in oropharynx cancer. She was laboratory chair of the ECOG E2303 protocol and demonstrated the association between RAS/PI3K pathway and resistance to cetuximab in head and neck squamous cell carcinoma (HNSCC). Her work highlighted the role of HRAS mutations in head and neck carcinogenesis, which subsequently became therapeutically relevant, as shown by encouraging results of tipifarnib in HRAS mutant HNSCC.

In 2007, Prof. Psyrri received her PhD from the National Kapodistrian University of Athens and joined the Faculty of Medicine in 2009. In 2012, Prof. Psyrri was appointed Head of Medical Oncology at Attikon University Hospital. In 2022, Prof. Psyrri was elected as the Chair of Medicine at the 2nd Propaedeutic Department of Internal Medicine & Translational Research Unit, which is the largest Clinical Department in Greece.

Prof. Psyrri's main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is a Steering Committee member of several industry-sponsored clinical trials and PI of investigator-initiated clinical trials. Her research projects are focused on combined immunotherapy to HNSCC, studying animal models of HPV-induced carcinogenesis and identifying predictors for response to PD1 inhibitors in HNSCC.

Between 2007 and 2015, Prof. Psyrri was Translational Research Chair of the EORTC Head and Neck Cancer Group. She is also the Chair of the Head and Neck Cancer Group of the Hellenic Cooperative Oncology Group (HeCOG) and founding member and European Representative of the Head and Neck Cancer Intergroup (HNCIG). From 2017-2021 Prof. Psyrri was scientific director of HECOG. In 2023, she was appointed Secretary of the International Head and Neck Cancer Group.

Prof. Psyrri is the Chair of the ESMO National Societies Committee, member of the ESMO Council and member of the ESMO Faculty for Head and Neck Cancer. In 2021 she was elected as Chair of the ESMO Nomination Committee for a 2-year term. She has been a Chair/Co-Chair and member of the Scientific Committee of the Head & Neck cancer track at several ESMO Congresses since 2015.

Prof. Psyrri has been invited as a Faculty Speaker at numerous international oncology conferences including ASCO Annual meetings, ESMO Congresses, American Head & Neck Society Meetings, American Society of Radiation Oncology Meeting, HPV Eurogin Conferences. She is a member of AACR, ASCO, EORTC, and the Society of Immunotherapy of Cancer (SITC). She is a founding member of Women for Oncology -Greece and a member of SITC's Women in Cancer Immunotherapy Network.

Prof. Psyrri has authored numerous peer-reviewed manuscripts and book chapters, has served as associate editor of 'Frontiers in Oncology" and became Deputy Editor of "Oral Oncology" in 2016. She is a member of the Editorial Board of Cancers, Annals of Oncology and Journal of Clinical Oncology.